EIKONOKLASTES THERAPEUTICS, INC. — SEC Form D Filing

EIKONOKLASTES THERAPEUTICS, INC. filed an SEC Form D on October 5, 2026, reporting $16.06M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 5, 2026
Amount reported
$16.06M
Round stage
Seed
Industry
Biotechnology
Website
https://eikonoklastes.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffer from severe neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), which cause progressive muscle degeneration, cognitive loss, and eventual death. These conditions have high unmet clinical needs with few effective treatment options beyond supportive care.

Solution

The company is developing ET-101 (SYNCAV1), a first-in-class, disease-modifying gene therapy that uses AAV9 to deliver additional copies of the Caveolin-1 gene to neurons. This therapy aims to overexpress Caveolin-1 to induce neuroprotection and neuroplasticity, helping nerve cells compensate for damage and improving functional ability in neurodegenerative diseases.

Verdict

This cleared because investors were funding a high-risk, high-reward bet on a novel gene therapy mechanism for severe neurodegenerative diseases, not because a clear path to market or a robust competitive moat was articulated. They implicitly bet on the scientific team's ability to validate the Caveolin-1 overexpression hypothesis in human trials, hoping for a breakthrough in an area with desperate unmet need. The limited upside stemmed from the binary nature of drug development success and the extensive capital requirements before any commercial viability.

Source: SEC EDGAR Form D filing